Skip to main content
. Author manuscript; available in PMC: 2023 Jan 30.
Published in final edited form as: J Mol Biol. 2021 Nov 10;434(2):167349. doi: 10.1016/j.jmb.2021.167349

Figure 5.

Figure 5.

Competition of the allosteric and catalytic sites for imatinib. (A) Stepwise titration of imatinib to the imatinib-resistance AblG269E/T334I variant monitored by NMR. (B,C) Stepwise titration of ATP to the AblY272H/A363V variant occupied with imatinib at both the catalytic and allosteric sites monitored by NMR.